From: An updated assessment of microglia depletion: current concepts and future directions
Pharmacological intervention | Efficiency | Time window | Physiological effects | References |
---|---|---|---|---|
CSF-1R inhibitor (PLX3397) | 99% | 21Â days | has no cognitive or behavioral impairments | [63] |
CSF-1R inhibitor (PLX3397) | ~90% | 21Â days | promotes brain recovery in intracerebral hemorrhage | [66] |
CSF-1R inhibitor (PLX3397) | ~90% | 21Â days | exacerbates brain recovery in brain ischemia | [69] |
CSF-1R inhibitor (PLX3397) | 97% | 21Â days | increases infarct size and brain injury after stroke | [67] |
CSF-1R inhibitor (PLX5622) | ~90% | 2 or 6Â weeks | ameliorates radiation-induced cognitive deficits | [70] |
CSF-1R inhibitor (PLX5622) | ~90% | 7Â days | ameliorates inflammation induced by neuronal lesion | [64] |
CSF-1R inhibitor (PLX5622) | ~80% | 28 days | prevents neuronal loss and contextual memory in Alzheimer’s | [65] |
CSF-1R inhibitor (GW2580) | Not shown | 6Â weeks | attenuates depression-like behavior and kidney function | [71] |
Liposomal clodronate | 70% | 2Â weeks | decreases anxiety and despair behaviors throughout life | [76] |
Liposomal clodronate | ~80% | 1 or 5Â days | alters spatial learning performance and social behavior | [75] |
Mac-1-saporin | 50% | 1Â day | triggers bone marrow derived-cell infiltration into spinal cord | [68] |